Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM-023 in Healthy Participants and Olmsted Syndrome Patients
NCT07090889Phase 1Recruiting
- Sponsor
- Orvida Pharma
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of ainuovirine in Olmsted syndrome (OLMS) (3 arms), sponsored by Orvida Pharma. Primary endpoint: Treatment-Emergent Adverse Events at Day 112. Started Jul 2025; status: recruiting.
02
Drugs
ainuovirine
03
Conditions
Olmsted syndrome (OLMS)
Beyond the preview
Go deeper on NCT07090889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090889.